IMPACTS OF SEMAGLUTIDE AND TIRZEPATIDE INDUCED WEIGHT LOSS ON FACIAL AESTHETICS: AN INTEGRATIVE LITERATURE REVIEW

Authors

  • Mauricio de Sousa Carvalho Reis Instituto Orofacial das Américas -IOA
  • Lilian Abreu Sousa Lopes Instituto Orofacial das Américas-IOA
  • Ludmila Tolstenko Nogueira Instituto Orofacial das Américas -IOA
  • Aniele Carvalho Lacerda Instituto Orofacial das Américas -IOA
  • Luciana Tolstenko Nogueira Instituto Orofacial das Américas -IOA
  • Antônio Marcolino Ferreira Segundo Instituto Orofacial das Américas -IOA
  • Maria Eduarda Mousinho Silva Rodrigues Instituto Orofacial das Américas -IOA
  • Kerolayny Lessa de Carvalho Lopes Instituto Orofacial das Américas -IOA

DOI:

https://doi.org/10.66104/d1j34g18

Keywords:

obesity; weightloss; facial aesthetics.

Abstract

The pursuit of improved metabolism and body aesthetics has intensified in recent years. Considering that obesity constitutes a global public health problem, there has been a significant increase in the use of weight-loss medications. This review aims to analyze the scientific evidence regarding the effects of weight loss on facial aesthetics associated with the use of tirrizepatide and semaglutide. For the study, the PubMed/MEDLINE, Scopus, and Web of Science databases were consulted, and the selected articles were analyzed descriptively and comparatively. The included studies demonstrated that accelerated weight loss can cause negative repercussions on facial aesthetics, such as loss of mechanical tissue support and excess skin, favoring the formation of deep wrinkles and alterations in facial proportions, characteristic of aging. It is concluded that GLP-1 receptor agonists and dual GLP-1/GIP    agonists are highly effective in weight reduction; However, they can negatively impact patients' self-esteem, both physically and emotionally, due to undesirable changes in facial aesthetics, highlighting the need for more systematic studies on the subject.

Downloads

Download data is not yet available.

References

BAGGETT, A. et al. Cosmetic considerations of semaglutide. Cosmetics, Basel, v. 12, n. 5, p. 221, 2025.

BURKE, O. M.; SA, B.; CESPEDES, D.; TOSTI, A. Dermatologic implications of glucagon-like peptide-1 receptor agonist medications. Skin Appendage Disorders, [S.l.], v. 11, n. 5, p. 416–423, 14 fev. 2025.

CARBONI, A.; MARTINI, O.; MARROQUIN, N. A.; WALLER, J. Natural weight loss or “Ozempic face”: demystifying a social media phenomenon. Journal of Drugs in Dermatology, New York, v. 23, n. 1, p. 1367–1368, 2024.

CATALAMO, L.; DE PONTE, F. S.; DE RINALDIS, D. “Ozempic face”: an emerging drug-related aesthetic concern and its treatment with endotissutal bipolar radiofrequency (RF)—our experience. Journal of Clinical Medicine, Basel, v. 14, n. 15, p. 5269, 2025.

DANESHGARAN, G.; SHAULY, O.; GOULD, D. J. “Ozempic face” in plastic surgery: a systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions. Aesthetic Surgery Journal Open Forum, Oxford, v. 7, p. ojaf056, 2025.

EL-AMAWY, H. S. et al. Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications – a comprehensive review. Anais Brasileiros de Dermatologia, Rio de Janeiro, 2026.

HAYKAL, D.; HERSANT, B.; CARTIER, H.; MENINGAUD, J. The role of GLP-1 agonists in esthetic medicine: exploring the impact of semaglutide on body contouring and skin health. Journal of Cosmetic Dermatology, Hoboken, 2024.

LAGO, R. M. et al. Tirzepatide versus GLP-1 receptor agonists in obesity management: metabolic outcomes and clinical implications. Obesity Reviews, Oxford, v. 26, n. 2, e13542, 2025.

RIDHA, Z.; FABI, S. G.; ZUBAIR, R.; DAYAN, S. H. Decoding the implications of glucagon-like peptide-1 receptor agonists on facial aging and accelerated skin aging. Aesthetic Surgery Journal, Oxford, v. 44, n. 11, p. NP809–NP818, nov. 2024.

RUBIO-HERRERA, M. A.; MERA-CARREIRO, S. Weight control treatment in obesity. Medicina Clínica (Barcelona), Barcelona, v. 165, n. 5, p. 107152, nov. 2025.

SEIDEL, M.. Rapid weight loss and facial aging: clinical implications of GLP-1 receptor agonists. Dermatologic Therapy, Hoboken, v. 38, n. 1, e15792, 2025.

SMITS, M. M.; VAN RAALTE, D. H. Safety of semaglutide. Frontiers in Endocrinology, Lausanne, v. 12, p. 645563, 7 jul. 2021. Erratum em: Frontiers in Endocrinology, Lausanne, v. 12, p. 786732, 10 nov. 2021.

Systematic Review on GLP-1RA-Induced Weight Loss and Body Contouring Surgeries. Retrospective association study correlating uso de GLP-1 com aumento de procedimentos estéticos (dados correlacionais e tendências indicadas em literatura científica).

ULLAH, M. I.; TAMANNA, S. Obesidade: impacto clínico, fisiopatologia, complicações e inovações modernas em estratégias terapêuticas. Medicines (Basel), Basel, v. 12, n. 3, p. 19, 28 jul. 2025.

VAMBE, S. D. Semaglutide (Ozempic®): a comprehensive review of its pharmacological properties and clinical applications. South African Pharmaceutical Journal, Johannesburg, v. 91, p. 32–38, 2024.

WORLD HEALTH ORGANIZATION. Obesity and overweight. Geneva: World Health Organization, 2023. Disponível em: https://www.who.int. Acesso em: 20 jan. 2025.

YANG, X. D.; YANG, Y. Y. Clinical pharmacokinetics of semaglutide: a systematic review. Drug Design, Development and Therapy, Auckland, v. 18, p. 2555–2570, 25 jun. 2024.

Downloads

Published

2026-03-19

Issue

Vol. 13 No. 03 (2026): REMUNOM - ISSN 2178-6925

Section

Artigos

License

Copyright (c) 2026 Mauricio de Sousa Carvalho Reis, Lilian Abreu Sousa Lopes, Ludmila Tolstenko Nogueira, Aniele Carvalho Lacerda , Luciana Tolstenko Nogueira, Antônio Marcolino Ferreira Segundo, Maria Eduarda Mousinho Silva Rodrigues , Kerolayny Lessa de Carvalho Lopes

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;

Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;

Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);

Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.

PRIVACY POLICY

The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.

Note: All content of the work is the sole responsibility of the author and the advisor.

How to Cite

IMPACTS OF SEMAGLUTIDE AND TIRZEPATIDE INDUCED WEIGHT LOSS ON FACIAL AESTHETICS: AN INTEGRATIVE LITERATURE REVIEW. (2026). REMUNOM, 13(03), 1-17. https://doi.org/10.66104/d1j34g18